UPDATE: West Pharma (WST) Q1 EPS Tops Views; Reaffirms Guidance
Get Alerts WST Hot Sheet
Price: $372.04 -1.4%
EPS Growth %: -34.3%
Financial Fact:
Interest expense: 2.2M
Today's EPS Names:
MAXN, CSTR, ACU, More
EPS Growth %: -34.3%
Financial Fact:
Interest expense: 2.2M
Today's EPS Names:
MAXN, CSTR, ACU, More
Join SI Premium – FREE
(Updated - April 27, 2017 9:16 AM EDT)
(Update corrects Q1 EPS)
West Pharma (NYSE: WST) reported Q1 EPS of $0.81, better than the analyst estimate of $0.55. First-quarter 2017 reported-diluted EPS includes the impact of a tax benefit of $0.21. Revenue for the quarter came in at $387.7 million versus the consensus estimate of $380.42 million.
- Reported net sales of $387.7 million grew 7.1% over the prior-year quarter. Net sales at constant currency grew by 8.7%.
- First-quarter 2017 reported-diluted EPS was $0.81, compared to prior-year quarter\'s results of reported-diluted EPS of $0.30 and adjusted-diluted EPS of $0.53. First-quarter 2017 reported-diluted EPS includes the impact of a tax benefit of $0.21 associated with the adoption of guidance issued by the Financial Accounting Standards Board (FASB) regarding share-based payment transactions.
- Reaffirming full-year 2017 sales and raising reported-diluted EPS guidance. Full-year 2017 sales guidance is unchanged and is expected to be between $1.585 billion to $1.610 billion. Full-year 2017 reported-diluted EPS guidance is now expected to be between $2.66 and $2.78, compared to the prior range of $2.45 and $2.57, and reflects the previously-discussed adoption of FASB-issued guidance.
For earnings history and earnings-related data on West Pharma (WST) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Growth isn't weak enough to truly undercut inflation pressures - BMO
- Wells Fargo on Super Micro Computer (SMCI): 'No Positive Preannouncement
- MetroCity Bankshares, Inc. (MCBS) Tops Q1 EPS by 4c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!